1Li YB, Xu W, Liao ZH, et al.Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function.Diabetes Care, 2004, 27:2597-2602.
2.
3Brange J, Owens DR, Kang S, et al.Monomeric insulins and their experimental and clinical implications.Diabetes Care, 1990, 13:923-954.
4Home PD, Barriocanal L, Lindholm A, et al.Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in health volunteers.Eur J Clin Pharmacol, 1999, 55:199-203.
5Heinemann L, Kapitza C, Starke A, et al.Time-action profile of the insulin analogue B28 Asp.Diabet Med, 1996, 13:683-684.
6.
7Bode BW, Strange P.Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.Diabetes Care, 2001, 24:69-72.
8Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). UK Prospective Diabetes Study(UKPDS)Group[J]. Lancet, 1998,352(9131): 854-65.
9Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). UK Prospective Diabetes Study(UKPDS)Group[J]. Lancet, 1998, 352(9131): 837-53.
10Zinman B. Insulin pump therapy and rapid acting insulin: What have learned[J]. Int Clin Suppl, 2001,(123):47.
